235 related articles for article (PubMed ID: 37108703)
1. GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
Balboni B; Masi M; Rocchia W; Girotto S; Cavalli A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108703
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays.
Balboni B; Tripathi SK; Veronesi M; Russo D; Penna I; Giabbai B; Bandiera T; Storici P; Girotto S; Cavalli A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409221
[TBL] [Abstract][Full Text] [Related]
3. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
5. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.
Bidon-Chanal A; Fuertes A; Alonso D; Pérez DI; Martínez A; Luque FJ; Medina M
Eur J Med Chem; 2013 Feb; 60():479-89. PubMed ID: 23354070
[TBL] [Abstract][Full Text] [Related]
7. Prediction of binding affinity of 1,2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3β: a molecular docking and dynamic simulation study.
Dinakar S; Gurubarath M; Dhananjayan K
J Biomol Struct Dyn; 2023 Jul; 41(11):4847-4862. PubMed ID: 35543239
[TBL] [Abstract][Full Text] [Related]
8. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
Bertrand JA; Thieffine S; Vulpetti A; Cristiani C; Valsasina B; Knapp S; Kalisz HM; Flocco M
J Mol Biol; 2003 Oct; 333(2):393-407. PubMed ID: 14529625
[TBL] [Abstract][Full Text] [Related]
10. Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease.
Shri SR; Manandhar S; Nayak Y; Pai KSR
Adv Pharm Bull; 2023 Nov; 13(4):688-700. PubMed ID: 38022801
[TBL] [Abstract][Full Text] [Related]
11. Stereoisomers of Schisandrin B Are Potent ATP Competitive GSK-3β Inhibitors with Neuroprotective Effects against Alzheimer's Disease: Stereochemistry and Biological Activity.
Hu XL; Guo C; Hou JQ; Feng JH; Zhang XQ; Xiong F; Ye WC; Wang H
ACS Chem Neurosci; 2019 Feb; 10(2):996-1007. PubMed ID: 29944335
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
13. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
14. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3β Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones.
Liang Z; Li QX
ACS Chem Neurosci; 2018 May; 9(5):1166-1183. PubMed ID: 29381861
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of Coumarin Derivatives as Versatile Scaffolds for GSK-3β Enzyme Inhibition.
Francisco CS; Javarini CL; de S Barcelos I; Morais PAB; de Paula H; de S Borges W; Neto ÁC; Lacerda V
Curr Top Med Chem; 2020; 20(2):153-160. PubMed ID: 31648640
[TBL] [Abstract][Full Text] [Related]
17. Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK-3β inhibitors.
Liu X; Yu J; Luo Y; Dong H
Chem Biol Drug Des; 2023 Feb; 101(2):326-339. PubMed ID: 35762873
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis and Biological Evaluation of 7-Chloro-9
Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
[TBL] [Abstract][Full Text] [Related]
19. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
